An article published this year in the
“Journal
of Cancer”
using one of our products, “FITC Apoptosis
Detection Kit”, by our customers from Greece, in the analysis of Potential
synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung
cancer. Congrats and Thanks.
Summay:
Lung cancer remains the leading cause of cancer-related deaths worldwide
and novel therapeutic approaches targeting crucial pathways are urgently needed
to improve its treatment. Differentiation-based therapeutics (Methylxanthines)
and phosphodiesterase inhibitors (type 4 and 5), have been implicated in cancer
treatment. Our objectives were to capture any potential anti-tumor effect of
these drug combinations with chemotherapeutic agents in vitro.
Conclusion: The synergistic effect of PDE inhibitors with platinum-based agents has been demonstrated in lung cancer. Our suggestion is that these combinations could be used as additive and maintenance treatment in combination to antineoplastic agents in lung cancer patients.
Reference:
Product link:
FITC Apoptosis
Detection kit with PI
No comments:
Post a Comment